United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 100 mg - major depressive disorder -sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. the efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical trials under clinical pharmacology). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation.  the antidepressant action of sertraline hyd

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine hydrochloride 20 mg - fluoxetine is indicated for the acute and maintenance treatment of major depressive disorder in adult patients and in pediatric patients aged 8 to18 years [see clinical studies (14.1)]. the usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods, should periodically be reevaluated [see dosage and administration (2.1)].   fluoxetine is indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with obsessive compulsive disorder (ocd) [see clinical studies (14.2)].  the effectiveness of fluoxetine in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. therefore, the physician who elects to use fluoxetine for extended periods, should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see dosage and administration (2.2)]. fluoxetine is indicated for the acute and maintenance treatment of bing

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate 5 mg - hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. this product should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen. patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. controlled substance – hydrocodone bitartrate and acetaminophen tablets are classified as a schedule iii controlled substance. abuse and dependence – psychic dependence, physical dependence, and tolerance may develop upon repeated administration of narcotics; therefore, this product should be prescribed and administered with caution. however, psychic dependence is unlikely to develop when hydrocodone bitartrate and acetaminophen tablets are used for a short time for the treatment of pain. physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant prop

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 5 mg - finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: -improve symptoms -reduce the risk of the need for surgery including transurethral resection of the prostate (turp) and prostatectomy. finasteride is contraindicated in the following: hypersensitivity to any component of this medication. pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to dht, finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. if this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. (see also warnings, exposure of women — risk to male fetus and precautions, information for patients and pregnancy.) in female rats, low doses of finasterid

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation. - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - folic acid 1 mg - folic acid is effective in the treatment of megaloblastic anemias due to deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. folic acid is contraindicated in patients who have shown previous intolerance to the drug.

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam 0.5 mg

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 1000 [usp'u] in 1 ml - heparin sodium injection, usp is indicated for: anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see dosage and administration ); prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism. heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures. heparin sodium should not be used in patients with the following conditions: severe thrombocytopenia; when suitable blood coagulation tests, e.g., the whole

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin sodium injection, usp is indicated for: anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see dosage and administration ); prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism. heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures. heparin sodium should not be used in patients with the following conditions: severe thrombocytopenia; when suitable blood coagulation tests, e.g., the whole

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg